Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study: A Randomized Clinical Trial
Open accessAbstract
Importance: Young mouse plasma restores memory in aged mice, but, to our knowledge, the effects are unknown in patients with Alzheimer disease (AD). Objective: To assess the safety, tolerability, and feasibility of infusions of young fresh frozen plasma (yFFP) from donors age 18 to 30 years in patients with AD. Design, Setting, and Participants: The Plasma for Alzheimer Symptom Amelioration (PLASMA) study randomized 9 patients under a double-blind crossover protocol to receive 4 once-weekly infusions of either 1 unit (approximately 250 mL) of yFFP from male donors or 250 mL of saline, followed by a 6-week washout and crossover to 4 once-weekly infusions of an alternate treatment. Patients and informants were masked to treatment and subjective measurements. After an open-label amendment, 9 patients received 4 weekly yFFP infusions only and their subjective measurements were unmasked. Patients were enrolled solely at Stanford University, a tertiary academic medical center, from September 2014 to December 2016, when enrollment reached its target. Eighteen consecutive patients with probable mild to moderate AD dementia, a Mini-Mental State Examination (score of 12 to 24 inclusive), and an age of 50 to 90 years were enrolled. Thirty-one patients were screened and 13 were excluded: 11 failed the inclusion criteria and 2 declined to participate. Interventions: One unit of yFFP from male donors/placebo infused once weekly for 4 weeks. Main Outcome and Measures: The primary outcomes were the safety, tolerability, and feasibility of 4 weekly yFFP infusions. Safety end point analyses included all patients who received the study drug/placebo. Results: There was no difference in the age (mean [SD], 74.17 [7.96] years), sex (12 women [67%]), or baseline Mini-Mental State Examination score (mean [SD], 19.39 [3.24]) between the crossover (n = 9) and open-label groups (n = 9). There were no related serious adverse events. One patient discontinued participation because of urticaria and another because of an unrelated stroke. There was no statistically significant difference between the plasma (17 [94.4%]) and placebo (9 [100.0%]) cohorts for other adverse events, which were mild to moderate in severity. The most common adverse events in the plasma group included hypertension (3 [16.7%]), dizziness (2 [11.1%]), sinus bradycardia (3 [16.7%]), headache (3 [16.7%]), and sinus tachycardia (3 [16.7%]). The mean visit adherence (n = 18) was 86% (interquartile range, 87%-100%) and adherence, accounting for a reduction in the total visit requirement due to early patient discontinuation, was 96% (interquartile range, 89%-100%). Conclusions and Relevance: The yFFP treatment was safe, well tolerated, and feasible. The study's limitations were the small sample size, short duration, and change in study design. The results warrant further exploration in larger, double-blinded placebo-controlled clinical trials. Trial Registration: ClinicalTrials.gov Identifier: NCT02256306.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Two recent clinical trials involving young plasma infusion in patients with AD and PD, respectively, have further validated this intervention strategy for neurodegenerative diseases.
“Two recent clinical trials involving young plasma infusion in patients with AD and PD, respectively, have further validated this intervention strategy for neurodegenerative diseases.73,74”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [73]
AD patients who received four weekly infusions of young fresh frozen plasma showed promising outcomes, supporting further exploration of long-term plasma therapy.
“AD patients who received four weekly infusions of young fresh frozen plasma showed promising outcomes, supporting further exploration of long-term plasma therapy.73”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [73]
A completed phase 1 trial of weekly infusions of 1 unit of young fresh frozen plasma from male donors versus saline in mild to moderate Alzheimer disease for 4 weeks was mostly well tolerated.
“A completed phase 1 trial of weekly infusions of 1 unit of young fresh frozen plasma from male donors (age 18-30) vs saline in patients with mild to moderate AD for total of 4 weeks demonstrated the intervention was mostly well tolerated (Sha et al., 2019).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Sha et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Correspondence of the brain's functional architecture during activation and rest
Smith, S. M., Fox, P. T., Miller, K. L., Glahn, D. C., Fox, P. M., Mackay, C. E., Filippini, N., Watkins, K. E., Toro, R., Laird, A. R., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905267106 · Cited by 5,150 · see citing works
Self-citationPermutation inference for the general linear model
Winkler, A. M., Ridgway, G. R., Webster, M. A., Smith, S. M., & Nichols, T. E. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.01.060 · Cited by 3,563 · see citing works
ICA-AROMA: A robust ICA-based strategy for removing motion artifacts from fMRI data
Pruim, R. H. R., Mennes, M., van Rooij, D., Llera, A., Buitelaar, J. K., & Beckmann, C. F. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.02.064 · Cited by 1,684 · see citing works
Self-citationYoung blood reverses age-related impairments in cognitive function and synaptic plasticity in mice
Villeda, S. A., Plambeck, K. E., Middeldorp, J., Castellano, J. M., Mosher, K. I., Luo, J., Smith, L. K., Bieri, G., Lin, K., Berdnik, D., et al. (2014) · Nature Medicine · doi:10.1038/nm.3569 · Cited by 1,081 · see citing works
Self-citationVascular and Neurogenic Rejuvenation of the Aging Mouse Brain by Young Systemic Factors
Katsimpardi, L., Litterman, N. K., Schein, P. A., Miller, C. M., Loffredo, F. S., Wojtkiewicz, G. R., Chen, J. W., Lee, R. T., Wagers, A. J., & Rubin, L. L. (2014) · Science · doi:10.1126/science.1251141 · Cited by 1,037 · see citing works
Human umbilical cord plasma proteins revitalize hippocampal function in aged mice
Castellano, J. M., Mosher, K. I., Abbey, R. J., McBride, A. A., James, M. L., Berdnik, D., Shen, J. C., Zou, B., Xie, X. S., Tingle, M., et al. (2017) · Nature · doi:10.1038/nature22067 · Cited by 445 · see citing works
Self-citationGpr158 mediates osteocalcin’s regulation of cognition
Khrimian, L., Obri, A., Ramos-Brossier, M., Rousseaud, A., Moriceau, S., Nicot, A.-S., Mera, P., Kosmidis, S., Karnavas, T., Saudou, F., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171320 · Cited by 308 · see citing works
Preclinical Assessment of Young Blood Plasma for Alzheimer Disease
Middeldorp, J., Lehallier, B., Villeda, S. A., Miedema, S. S. M., Evans, E., Czirr, E., Zhang, H., Luo, J., Stan, T., Mosher, K. I., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3185 · Cited by 153 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · see citing works
Undulating changes in human plasma proteome profiles across the lifespan
Lehallier, B., Gate, D., Schaum, N., Nanasi, T., Lee, S. E., Yousef, H., Moran Losada, P., Berdnik, D., Keller, A., Verghese, J., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0673-2 · Cited by 981 · see citing works
Self-citationApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756 · see citing works
The quest to slow ageing through drug discovery
Partridge, L., Fuentealba, M., & Kennedy, B. K. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0067-7 · Cited by 468 · see citing works
Aging and Rejuvenation of Neural Stem Cells and Their Niches
Navarro Negredo, P., Yeo, R. W., & Brunet, A. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.07.002 · Cited by 246 · see citing works
Systemic factors as mediators of brain homeostasis, ageing and neurodegeneration
Pluvinage, J. V., & Wyss-Coray, T. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0255-9 · Cited by 191 · see citing works
Self-citationLei, Q., Gao, F., Liu, T., Ren, W., Chen, L., Cao, Y., Chen, W., Guo, S., Zhang, Q., Chen, W., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz8697 · Cited by 170 · see citing works
Chen, X., Luo, Y., Zhu, Q., Zhang, J., Huang, H., Kan, Y., Li, D., Xu, M., Liu, S., Li, J., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00612-4 · Cited by 174 · see citing works
Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165 · see citing works
Young bone marrow transplantation preserves learning and memory in old mice
Das, M. M., Godoy, M., Chen, S., Moser, V. A., Avalos, P., Roxas, K. M., Dang, I., Yáñez, A., Zhang, W., Bresee, C., et al. (2019) · Communications Biology · doi:10.1038/s42003-019-0298-5 · Cited by 98 · see citing works
Manta, C.-P., Leibing, T., Friedrich, M., Nolte, H., Adrian, M., Schledzewski, K., Krzistetzko, J., Kirkamm, C., David Schmid, C., Xi, Y., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.058615 · Cited by 84 · see citing works
Can exercise training teach us how to treat Alzheimer's disease?
Huuha, A. M., Norevik, C. S., Moreira, J. B. N., Kobro-Flatmoen, A., Scrimgeour, N., Kivipelto, M., Van Praag, H., Ziaei, M., Sando, S. B., Wisløff, U., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101559 · Cited by 79 · see citing works
Lindbohm, J. V., Mars, N., Walker, K. A., Singh‐Manoux, A., Livingston, G., Brunner, E. J., Sipilä, P. N., Saksela, K., Ferrie, J. E., Lovering, R. C., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12419 · Cited by 70 · see citing works
Morató, X., Pytel, V., Jofresa, S., Ruiz, A., & Boada, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169305 · Cited by 53 · see citing works
Clement, J., Yan, Q., Agrawal, M., Coronado, R. E., Sturges, J. A., Horvath, M., Lu, A. T., Brooke, R. T., & Horvath, S. (2022) · Aging Cell · doi:10.1111/acel.13696 · Cited by 34 · see citing works
Safety of Plasma Infusions in Parkinson's Disease
Parker, J. E., Martinez, A., Deutsch, G. K., Prabhakar, V., Lising, M., Kapphahn, K. I., Anidi, C. M., Neuville, R., Coburn, M., Shah, N., et al. (2020) · Movement Disorders · doi:10.1002/mds.28198 · Cited by 23 · see citing works
Self-citationKang, S., Moser, V. A., Svendsen, C. N., & Goodridge, H. S. (2020) · Communications Biology · doi:10.1038/s42003-020-0797-4 · Cited by 22 · see citing works
- Authors
- Sha, S. J., Deutsch, G. K., Tian, L., Richardson, K., Coburn, M., Gaudioso, J. L., Marcal, T., Solomon, E., Boumis, A., Bet, A., Mennes, M., van Oort, E., Beckmann, C. F., Braithwaite, S. P., Jackson, S., Nikolich, K., Stephens, D., Kerchner, G. A., & Wyss-Coray, T.
- Affiliations
- Stanford University (US)
- Department of Health Research and Policy, Stanford University, Stanford, California
- Science37, San Francisco, California
- Stanford Medicine (US)
- University of Southern California (US)
- SBGneuro Ltd, Oxford, England
- Alkahest, Inc. (United States) (US)
- Department of Neurology and Neurological Sciences, Stanford University, Stanford, California
- Corresponding author
- Sha, Sharon J.
- ORCID
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2019-01-01
- Volume
- 76
- Issue
- 1
- Pages
- 35
- ISSN
- 2168-6149 (ISSN-L)
- PMC
- PMC6439869
- OpenAlex
- W2899249431
- Cited by
- 109
- References
- 9
- Citations by year
- 2026: 8 · 2025: 8 · 2024: 19 · 2023: 7 · 2022: 21 · 2021: 12 · 2020: 22 · 2019: 11 · 2018: 1
- FWCI
- 7.88
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institute on Aging (P50AG047366, R01AG048076)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Biochemistry › Blood transfusion and management
- Keywords
- Alzheimer's disease, plasma therapy, safety and tolerability, feasibility, mild to moderate dementia, adverse events, age-related memory decline, double-blind crossover trial, open-label extension, urticaria, stroke, executive function, quality of life, caregiver burden
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Alzheimer Disease, Double-Blind Method, Feasibility Studies, Female, Humans, Male, Plasma, Treatment Outcome, Blood Component Transfusion, Cross-Over Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
